Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects

Abstract Diminazene aceturate (DIZE) is an anti‐protozoan compound that has been previously reported to increase the activity of the angiotensin‐converting enzyme 2 (ACE2) and thus increase Angiotensin‐(1‐7) production, leading to cardioprotection against post‐myocardial infarction dysfunction and structural remodelling. Moreover, DIZE is able to ameliorate morpho‐functional changes after myocardial infarction by enhancing ACE2 activity, thus increasing Angiotensin‐(1‐7) production (a benefic peptide of the renin‐angiotensin system). However, despite the improvement in cardiac function/structure, little is known about DIZE effects on arrhythmia suppression, contraction/excitable aspects of the heart and importantly its mechanisms of action. Thus, our aim was to test the acute effect of DIZE cardioprotection at the specific level of potential antiarrhythmic effects and modulation in excitation‐contraction coupling. For this, we performed in vitro and in vivo techniques for arrhythmia induction followed by an acute administration of DIZE. For the first time, we described that DIZE can reduce arrhythmias which is explained by modulation of cardiomyocyte contraction and excitability. Such effects were independent of Mas receptor and nitric oxide release. Development of a new DIZE‐based approach to ameliorate myocardial contractile and electrophysiological dysfunction requires further investigation; however, DIZE may provide the basis for a future beneficial therapy to post‐myocardial infarction patients.